SYNAIRGEN PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.19 GBX | -0.80% |
|
-8.16% | +3.60% |
| May. 07 | AstraZeneca target raised; Antofagasta lowered | AN |
| 2023 | FTSE 100 Finishes Slightly Lower After Steady Session | DJ |
Financials (USD)
| Sales 2023 * | - | Sales 2024 * | - | Capitalization | 12.57M |
|---|---|---|---|---|---|
| Net income 2023 * | -9M | Net income 2024 * | -6M | EV / Sales 2023 * | - |
| Net cash position 2023 * | 10.81M | Net cash position 2024 * | 5.5M | EV / Sales 2024 * | - |
| P/E ratio 2023 * |
-1.4
x | P/E ratio 2024 * |
-2.09
x | Employees | 34 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 96.93% |
More Fundamentals
* Assessed data
More news
More news
| 1 day | -0.80% | ||
| 1 week | -8.16% | ||
| Current month | -10.42% | ||
| 1 month | -4.92% | ||
| 3 months | +7.75% | ||
| 6 months | -20.64% | ||
| Current year | +3.60% |
1 week
6.01
7.20
1 month
5.728.00
Current year
4.0010.00
1 year
4.0011.00
3 years
4.00223.80
5 years
4.00260.00
10 years
4.00260.00
| Managers | Title | Age | Since |
|---|---|---|---|
Richard Marsden
CEO | Chief Executive Officer | 57 | 03-10-31 |
Joseph Colliver
DFI | Director of Finance/CFO | 43 | Nov. 05 |
Marcin Mankowski
CTO | Chief Tech/Sci/R&D Officer | - | 23-10-02 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Simon Shaw
CHM | Chairman | 59 | 03-05-31 |
Stephen Holgate
FOU | Founder | 77 | 03-05-31 |
Richard Marsden
CEO | Chief Executive Officer | 57 | 03-10-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-11 | 6.19 | -0.80% | 364 357 |
| 24-06-10 | 6.24 | -6.31% | 633,931 |
| 24-06-07 | 6.66 | +1.68% | 635,627 |
| 24-06-06 | 6.55 | -3.53% | 561,492 |
| 24-06-05 | 6.79 | +0.74% | 477,661 |
Delayed Quote London S.E., June 11, 2024 at 11:35 am EDT
More quotes
Synairgen plc is a United Kingdom-based holding company for Synairgen Research Limited, which is a respiratory drug discovery and development company. The Company is developing SNG001, an investigative formulation of inhaled interferon beta (IFN-B), for the treatment and prevention of various viral lung infections in high-risk patient groups. The Company has developed and is testing an inhaled formulation of IFN-B designed to directly target the lungs, the primary site of many viral lung infections, including COVID-19.
Calendar
2024-09-25
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.0624
GBP
Average target price
0.08
GBP
Spread / Average Target
+28.21%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +3.60% | 15.99M | |
| +48.85% | 56.95B | |
| +39.98% | 40.26B | |
| -7.13% | 39.32B | |
| -4.42% | 28.37B | |
| +12.33% | 26.45B | |
| -18.07% | 19.41B | |
| +29.54% | 12.54B | |
| +26.07% | 12.21B | |
| -0.71% | 12.15B |
- Stock Market
- Equities
- SNG Stock
